INNATE PHARMA (IPH) — key financial figures for fiscal year 2024 (in EUR), standardized from XBRL/iXBRL filings by Hub-Equity:

Revenue (FY2024)

€20.1M

Net Income/Loss (FY2024)

-€49.5M

Total Assets (FY2024)

€111.1M

Total Equity (FY2024)

€8.8M

Cash Flows from Operating Activities (FY2024)

-€6.9M

Source: INNATE PHARMA annual_report filing (FY2024). Full income statement, balance sheet and cash flow, restatement-aware and traceable to the source filing, at Hub-Equity.